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Abstract
Background: To date, very little information is available concerning the relationship between acanthosis nigricans
(AN) and infection with human immunodeficiency virus type 1 (HIV-1).
Case presentation: Herein, we report the case of a middle-aged man admitted for fever and progressively
worsening dyspnea in the context of an opportunistic pneumonia and firstly diagnosed with acquired
immunodeficiency syndrome (AIDS). At the time of diagnosis, physical examination revealed the presence of a
palpable, hyperpigmented skin lesion on the left areola with surface desquamation and velvety texture consistent
with AN. Of note, the most common primary etiologies related to AN were excluded and the complete regression
of the skin lesion was observed once antiretroviral therapy was started.
Conclusion: This is the second report of AN found in patients with AIDS and apparently responsive to prolonged
antiretroviral treatment. Possible explanations of this association are still not completely understood, probably
related to virus-induced changes in lipid metabolism. Our experience suggests that HIV testing should always be
considered in the setting of apparently idiopathic AN.
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Background
Acanthosis nigricans (AN) is characterised by a darkly
pigmented skin lesion, usually localised in intertriginous
areas, usually palpable with a velvety texture. Histo-
pathological features of AN typically include epidermal
and dermal hyperplasia with orthokeratotic hyperkera-
tosis, papillomatosis of the stratum spinosum and basal
layer hyperpigmentation [1]. AN can be associated with
several conditions, especially metabolic syndrome, insu-
lin resistance, endocrinopathies, malignancies, and some
medications [1, 2]. Interestingly, treatment is not clear,
but if secondary to malignancy AN disappears with
tumor eradication [1].
Findings of human immunodeficiency virus (HIV)-as-
sociated AN are anecdotal and only poor information is
available from literature regarding this issue. Maltez
et al. [3] firstly reported a case of a patient with AIDS
who presented with three opportunistic infections and
concomitant AN. In that case, AN disappeared after
starting antiretroviral therapy (ART). Similarly, we here
report a case of AN in the setting of a newly-diagnosed
AIDS, which successfully regressed after a prolonged
course with raltegravir and tenofovir/emtricitabine com-
bination therapy.
Case report
A 51-year-old man was admitted to our General Medi-
cine Division complaining of intermittent fever (up to
40 °C) and progressively worsening dyspnea associated
with fatigue and weight loss. His medical history was
positive for arterial hypertension on treatment with
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olmesartan and hydrochlorothiazide; neither further
medical disorders nor other medications were reported.
On admission, physical examination revealed diffused bi-
lateral crackles at chest auscultation and the presence of
a palpable, hyperpigmented skin lesion on the left areola
with surface desquamation and velvety texture (Fig. 1a).
The patient had no known previous dermatosis. Oropha-
ryngeal candidiasis was also present. No further abnor-
malities were found at physical examination.
Blood count revealed normocytic anemia (hemoglobin
9 g/dL) and lymphopenia (total lymphocytes 380/μL).
Arterial blood gases analysis showed moderate hypox-
emia (pO2 71 mmHg) and hypocapnia (pCO2 30mmHg).
Chest X-ray revealed the presence of multiple parenchy-
mal infiltrates, while cysts of Pneumocystis jirovecii were
detected in bronchoalveolar lavage samples. Diagnosis of
P. jirovecii pneumonia was made and the patient was
started on combination treatment with trimethoprim/
sulfamethoxazole (160/800 mg, 2 tablets per os q8h) and
fluconazole (200 mg per os q24h).
Considering the opportunistic nature of P. jirovecii
pulmonary disease, HIV-1 infection was suspected. Ser-
ology was positive for HIV-1 antibodies at both ELISA
and western blot confirmatory testing; plasma HIV-1
RNA levels revealed high viral load (325,000 copies/mL).
CD4+ T cell count showed a profound immunosuppres-
sion (37 cells/μL). HIV-1 genotypic drug resistance test
was then performed, showing the presence of a wild-
type virus (CRF12_BF). HLA-B*5701 tested negative.
Cytomegalovirus (CMV) viremia was also detected (1412
copies/mL). Therefore, diagnosis of acquired immuno-
deficiency syndrome (AIDS) was established and the pa-
tient was subsequently started on antiretroviral therapy
(ART) with raltegravir 400 mg per os q12h and tenofo-
vir/emtricitabine fixed-dose combination per os q24h.
Excisional skin biopsy of the left areola lesion was per-
formed and revealed focal hyperkeratosis, mild papillo-
matosis, and hyperpigmentation of the basal layer.
Dermal papillae projected upwards as finger-like projec-
tions with prominent verticalisation of subepithelial ves-
sels and scattered deposition of melanophages. The
valleys between papillae showed mild acanthosis and
seemed occasionally filled with keratotic material. These
findings were overall consistent with a diagnosis of AN
(Fig. 2). Commonly associated diagnoses as malignancies
and endocrine disorders, as well as drug-related forms of
AN, were excluded. Particularly, obesity and abnormal-
ities in lipid profile as well as in glucose metabolism and
insulin sensitivity were excluded. Indeed, patient’s body
mass index was 24.3 kg/m2 and baseline fasting blood
tests at admission – i.e. before starting ART – showed
normal values of serum total cholesterol (3.62 mmol/L),
low-density lipoprotein (LDL, 2.25 mmol/L), high-
density lipoprotein (HDL, 0.91 mmol/L), triglycerides
(1.01 mmol/L), as well as normal fasting glucose (5.1
mmol/L) and glycated hemoglobin (5.4%). Moreover,
oral glucose tolerance test was performed as soon as AN
diagnosis was confirmed and tested negative, too (fasting
glucose: 4.8 mmol/L, 120-min glucose: 6.3 mmol/L).
Fasting insulin at the time of oral glucose tolerance test
was 7.2 μU/mL.
Interestingly, progressive improvement in AN size and
pigmentation was observed after starting ART and
complete regression was confirmed at one-year follow-
up visit (Fig. 1b).
Discussion and conclusion
AN is characterised by velvety, hyperpigmented plaques
typically localised on intertriginous areas of the body
surface. AN is commonly considered a cutaneous
marker of insulin resistance. Indeed, the most frequently
associated disorders are obesity, diabetes mellitus and
every other condition linked to insulin resistance; how-
ever, in some cases, AN can be associated with internal
malignancies, especially abdominal adenocarcinomas [1].
Genetic disorders and medications that cause hyperinsu-
linemia (i.e. glucocorticoids, HIV protease inhibitors, in-
sulin, etc. [1, 4]) represent others secondary etiologies.
Occasionally, AN occurs independently from all of the
above-mentioned conditions.
In our case the patient did not suffer from any medical
disorder usually linked to AN, however he was affected
Fig. 1 Skin lesion at the time of patient’s admission (a) and after one year of ART treatment (b). See text for further explanation
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by HIV-1 infection. To our knowledge, this is the second
case described of an AIDS subject diagnosed with P. jiro-
vecii pneumonia and AN, the latter regressing once ART
was initiated. Maltez et al. firstly reported in 1997 a case
of a patient with AIDS complicated by three concurrent
opportunistic infections and associated with AN [3].
Similarly to what observed in our case, AN disappeared
after starting antiretroviral treatment.
The reasons behind this association are not completely
clear, but this phenomenon might be linked to HIV-
induced changes in the endocrine homeostasis. In fact,
hyperinsulinemia seems to play a key role in the devel-
opment of AN [5, 6], favoring the bond between insulin
and growth factor receptors similar to insulin receptors,
which stimulate keratinocytes and fibroblasts prolifera-
tion in the dermis [4]. According to literature [7, 8],
HIV-1 patients have specific risk factors for metabolic
syndrome and hyperinsulinemia compared with general
population, such as chronic inflammation caused by per-
sistent viral replication in the reservoirs despite effective
antiretroviral treatments [9]. Moreover, other studies
have described that some inflammatory mediators are
involved in insulin resistance and diabetes development
[10]. HIV-1 infection itself can contribute to the devel-
opment of metabolic syndrome by decreasing the activ-
ity of lipoprotein lipase and hepatic lipase, allowing
increase in triglycerides and total cholesterol blood con-
centrations [11, 12]. Indeed, it is also known that higher
HIV-1 RNA levels are associated with lower LDL choles-
terol and higher VLDL cholesterol and triglycerides [13].
Other data suggest that metabolism in HIV-1-infected
patients is characterised by increased resting energy ex-
penditure and a de novo hepatic lipogenesis [14]. Duro
M et al. [7] reported that the risk of developing meta-
bolic syndrome is lowered in HIV-1-infected patients
when viral RNA load decreases after treatment. On the
other hand, AN is also considered a manifestation of in-
sulin resistance among patients with HIV-1 infection
who are already on treatment with protease inhibitors
[4, 15]. These findings are apparently contradictory, but
suggest the presence of intricate mechanisms that may
be involved in the occurrence of metabolic syndrome
and AN among HIV-1 patients. Moreover, multiple
endocrinopathies have been reported in HIV-1-infected
subjects, such as dyslipidemia, osteoporosis and adrenal
insufficiency [16]. In this setting, adrenalitis due to CMV
infection is a well-recognised condition in AIDS patients
[17], suggesting a possible role of CMV in the development
of AN. In our case, CMV viremia was detected (1412 cop-
ies/mL), however no electrolyte disturbance neither
hypotension suspicious for adrenal failure were observed.
In conclusion, our experience suggests that HIV-1 infec-
tion – particularly in the setting of AIDS – may be associated
with AN, which in turn seems to respond successfully to
ART. Based on this data, HIV-1 testing should always be
considered in the differential diagnosis of AN.
Abbreviations
HIV-1: human immunodeficiency virus type 1; AN: acanthosis nigricans;
AIDS: acquired immunodeficiency syndrome; CMV: cytomegalovirus;
ART: antiretroviral therapy; VLDL: very low-density lipoprotein; LDL: low-
density lipoprotein; HDL: high-density lipoprotein
Acknowledgements
Not applicable.
Authors’ contributions
All authors contributed significantly to the work of this report. AI, IM, MDP
and PP conceptualised the paper, collected clinical data and wrote the
report; GS and LDV performed biopsy and provided pathology data and
figures. The final version of this manuscript has been read and approved by
all authors and it is not under consideration for publication elsewhere.
Funding
No funding was received.
Availability of data and materials
All data generated or analysed during this study are included in this
published article. All original data is available in the corresponding author.
Ethics approval and consent to participate
Any permission from the hospital was not required. This was because of all
data was obtained from usual clinical process.
Consent for publication
Written informed consent was obtained from the patient for publication of
this Case Report and any accompanying images.
Competing interests
The authors report no conflict of interest.
Author details
1Department of Public Health and Infectious Diseases, “Sapienza” University
of Rome, Rome, Italy. 2Department of Translational and Precision Medicine,
“Sapienza” University of Rome, Rome, Italy. 3Department of Molecular
Medicine, “Sapienza” University of Rome, Rome, Italy.
Fig. 2 Hematoxylin and eosin stain 10x magnification of skin lesion
biopsy showing focal hyperkeratosis, mild papillomatosis, and
hyperpigmentation of the basal layer, consistent with the diagnosis
of AN (see text for further details)
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